论文部分内容阅读
目的 :观察赛庚啶对偏头痛疗效及血浆 β_内啡肽和蛋氨酸脑啡肽的影响。方法 :采用前瞻性、双盲法给 10例健康志愿者和 38例偏头痛病人 (男性15例 ,女性 2 3例 ,年龄 37a±s 10a)分别服用赛庚啶 4mg ,8mg和 12mg ,bid× 12wk。于wk 4,wk8,wk 12后观察头痛日数和指数的改变 ,并测定发作期和间歇期血浆内上述 2种阿片肽。结果 :赛庚啶和安慰剂均使头痛日数和指数明显下降 ,使发作期和间歇期 2种阿片肽血浆浓度显著升高。结论 :赛庚啶可促进 β_内啡肽分泌 ,减少活性物质释放 ,促进蛋氨酸脑啡肽分泌使对疼痛的抑制增强 ,在 8mg剂量或以上时对偏头痛有效
Objective: To observe the effect of cyproheptadine on migraine and plasma β-endorphin and methionine enkephalin. Methods: A total of 10 healthy volunteers and 38 migraineurs (15 males and 23 females, 37a ± s 10a) were enrolled in this prospective, double-blind trial. Cyproheptadine 4mg, 8mg and 12mg bid × 12wk. After wk 4, wk8, wk 12, the changes of headache days and indexes were observed, and the above two kinds of opioid peptides were measured in the seizure phase and intermittent phase. Results: Both cyproheptadine and placebo significantly decreased the days and indices of headache, leading to a significant increase in plasma concentrations of both opioids during the episodes and intermission periods. Conclusion: Cyproheptadine can promote the secretion of β-endorphin, reduce the release of active substances and promote the inhibition of pain by methionine enkephalin secretion, which is effective for migraine at 8mg dose or above